ReviewMarine drugs2020
Impact of Astaxanthin on Diabetes Pathogenesis and Chronic Complications.
Review in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 137 citations in OpenAlex.
- Exploring the Multifunctional Benefits of Astaxanthin in Aging, Oxidative Stress, Immune Dysfunction, Gut and Skin Health.Antioxidants (Basel, Switzerland) · 2026Review
- Astaxanthin Delivery Across Administration Routes: Recent Advances to Improve Stability and Bioavailability.Pharmaceutics · 2026Review
- Heterologous Production of 2,2'-Dihydroxy Derivatives of Astaxanthin and Adonirubin inAntioxidants (Basel, Switzerland) · 2026Article
- Effects of Astaxanthin Supplementation on Glycemic Control and Lipid Profile in Patients With Prediabetes and Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Nutrition and metabolic insights · 2026Review
- Molecular pathways of oxidative stress in diabetes: redox imbalance and insulin pathway dysregulation.Molecular biology reports · 2025Review
- Food-grade nanostructured delivery systems for oral administration of astaxanthin: Bioprocessing strategies and therapeutic applications.NPJ science of food · 2025Review
- Combined supplementation of leucine and glutamine acts as a novel therapeutic approach to alleviate hyperglycemia and oxidative stress by targeting insulin signalling genes in a drosophila model of type 2 diabetes.Molecular biology reports · 2025Article
- Astaxanthin mitigates diabetic cardiomyopathy and nephropathyin HF/HFr/STZ diabetic rats via modulating NOX4, fractalkine, Nrf2, and AP-1 pathways.Scientific reports · 2025Article
- Production Methods, Biological Activity and Potential Application Prospects of Astaxanthin.Foods (Basel, Switzerland) · 2025Review
- Marine-Derived Astaxanthin: Molecular Mechanisms, Biomedical Applications, and Roles in Stem Cell Biology.Marine drugs · 2025Review
- Carotenoids for Antiaging: Nutraceutical, Pharmaceutical, and Cosmeceutical Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Unveiling astaxanthin: biotechnological advances, delivery systems and versatile applications in nutraceuticals and cosmetics.Archives of microbiology · 2025Review
- Astaxanthin-loaded PLGA nanoparticles inhibit survival of MKN-45 gastric cancer cell line by modulating JAK2/STAT3/mTOR/PI3K pathway.BMC cancer · 2025Article
- Article
- Plasma-based proteomics analysis of molecular pathways in canine diabetes mellitus after astaxanthin supplementation.PloS one · 2025Article
- The protective role of Astaxanthin against oxidative stress and inflammation in peritoneal dialysis rats.BioMedicine · 2025Article
- Astaxanthin is a Novel Candidate for Glioblastoma Treatment? A Review.Current medicinal chemistry · 2025Review
- Targeting oxidative stress in diabetic retinopathy: mechanisms, pathology, and novel treatment approaches.Frontiers in immunology · 2025Review
- Astaxanthin attenuates diabetic kidney injury through upregulation of autophagy in podocytes and pathological crosstalk with mesangial cells.Renal failure · 2024Article
- Exploration of the Biotechnological Potential of Two Newly IsolatedFoods (Basel, Switzerland) · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress (OS) plays a pivotal role in diabetes mellitus (DM) onset, progression, and chronic complications. Hyperglycemia-induced reactive oxygen species (ROS) have been shown to reduce insulin secretion from pancreatic β-cells, to impair insulin sensitivity and signaling in insulin-responsive tissues, and to alter endothelial cells function in both type 1 and type 2 DM. As a powerful antioxidant without side effects, astaxanthin (ASX), a xanthophyll carotenoid, has been suggested to contribute to the prevention and treatment of DM-associated pathologies. ASX reduces inflammation, OS, and apoptosis by regulating different OS pathways though the exact mechanism remains elusive. Based on several studies conducted on type 1 and type 2 DM animal models, orally or parenterally administrated ASX improves insulin resistance and insulin secretion; reduces hyperglycemia; and exerts protective effects against retinopathy, nephropathy, and neuropathy. However, more experimental support is needed to define conditions for its use. Moreover, its efficacy in diabetic patients is poorly explored. In the present review, we aimed to identify the up-to-date biological effects and underlying mechanisms of ASX on the ROS-induced DM-associated metabolic disorders and subsequent complications. The development of an in-depth research to better understand the biological mechanisms involved and to identify the most effective ASX dosage and route of administration is deemed necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.